28 April, 2026 in Investor Relations Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia
22 April, 2026 in Investor Relations Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment
15 April, 2026 in Investor Relations Nexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and China
14 April, 2026 in Investor Relations Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21
09 April, 2026 in Investor Relations Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents
